menu
    • menu
    [{"orgOrder":0,"company":"Parvus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"PVT-401","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Parvus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parvus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Parvus Therapeutics \/ AbbVie Inc"}]

    Find Gastroenterology Clinical Drug Pipeline Developments & Deals by Parvus Therapeutics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Parvus Therapeutics

                            U.S.A arrow
                            Arvo
                            Not Confirmed

                            Parvus Therapeutics

                            U.S.A arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PVT-401

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Parvus Collaborates with AbbVie to Develop IBD Therapies Using Navacim Technology

                            Details : AbbVie partners with Parvus to develop immunotherapies for Inflammatory Bowel Disease (IBD) using Parvus' Navacim Treg platform, including PVT-401.

                            Product Name : PVT-401

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : PVT-401

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth